Document is current

Article History

Received: 27 October 2017

Accepted: 19 February 2018

First Online: 2 March 2018

Ethics approval and consent to participate

: The protocol was approved by the Clinical Trial Review Committee of the Thoracic Oncology Research Group and the Institutional Review Board or Ethics Committee of Kanagawa Cardiovascular and Respiratory Center, Kanagawa Cancer Center, Kitasato University Hospital, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Fujisawa City Hospital, Ibaraki Prefectural Central Hospital, and Yokohama Municipal Citizen’s Hospital. All patients provided written informed consent.

: Not applicable.

: Ikeda S, Ogura T, Sekine A, Oda T, Igawa S, Katono K, Otani S, Yamada K, Saito H, Kondo T, Nishikawa M, and Sakamaki K declare no potential conflicts of interest with any companies/organizations, whose products or services may be discussed in this article. Kato T received honoraria from Chugai Pharmaceutical, Roche, Boehringer Ingelheim Japan, Ono Pharmaceutical, Eli Lilly Japan, AstraZeneca, Taiho Pharmaceutical, Pfizer Japan, and Kyowa Hakko Kirin. Masuda N has received honoraria from Pfizer Japan, Bristol Myers Squibb, and Ono Pharmaceutical. Hosomi Y and Nakahara Y received honoraria from Chugai Pharmaceutical. Yamanaka T received honoraria from Chugai Pharmaceutical, Takeda Pharmaceutical, Boehringer Ingelheim, Taiho Pharmaceutical, and research funds from Takeda Pharmaceutical and Taiho Pharmaceutical. Okamoto H received honoraria from Takeda Pharmaceutical, MSD, Ono Pharmaceutical, Astrazeneca, Merck, Chugai Pharmaceutical, Taiho Pharmaceutical, Bristol Myers Squibb, Eli Lilly Japan, and Daiich Sankyo.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.